Delivery Order SPE2DB24D2100-SPE2DB25FBFST
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $10,947.00 to AmerisourceBergen Drug Corp for the supply of Gel-One 30 mg/3 mL syringes on July 28, 2025, with completion scheduled for August 18, 2025. This firm fixed-price delivery order, placed under a competitive procurement with no set-aside designation, will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. Gel-One is a viscosupplementation product used primarily for joint pain management,...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $18,245 for Gel-One 30 mg/3 mL syringes on August 4, 2025, with completion expected by August 25, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Gel-One is a viscosupplement injection used primarily for knee osteoarthritis treatment, representing a specialized medical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Gel-One 30 mg/3 mL syringes with a ceiling value of $3,649.00 and an ultimate completion date of August 13, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded to the prime contractor. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $18,245 delivery order to AmerisourceBergen Drug Corp for Gel-One 30 mg/3 mL syringes on August 7, 2025, with an ultimate completion date of August 28, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026. The company, headquartered in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,649 to AmerisourceBergen Drug Corp for Gel-One 30 mg/3 mL syringes on August 5, 2025, with completion scheduled for August 26, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents a single pharmaceutical supply transaction within the company's broader federal contract portfolio. The product will be delivered to AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,649.00 to AmerisourceBergen Drug Corp for the supply of Gel-One 30 mg/3 mL syringes. This competitive, firm fixed-price delivery order, issued on July 22, 2025, is scheduled for completion by August 12, 2025, with performance taking place at the contractor's corporate office in Conshohocken, Pennsylvania. The contract carries no set-aside designation, indicating it was awarded through open competition to this established...
- The Defense Logistics Agency awarded a $4,378.80 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Gel-One 30 mg/3 mL syringes on July 30, 2025, with an ultimate completion date of August 20, 2025. This is a non-set-aside contract executed under the company's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion global pharmaceutical support vehicle valued through December 2026. The place of performance is AmerisourceBergen's corporate...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,649.00 to AmerisourceBergen Drug Corp for the supply of Gel-One 30 mg/3 mL syringes. This firm fixed-price delivery order, issued on August 4, 2025, with an ultimate completion date of August 25, 2025, represents a competitive award with no set-aside designation. The product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office. As a child order...
- The Defense Logistics Agency awarded a delivery order valued at $1,824.50 to AmerisourceBergen Drug Corp for the supply of Gel-One 30 mg/3 mL syringes on July 30, 2025, with an ultimate completion date of August 20, 2025. This competitive contract award, which carries no set-aside designation, is structured as a firm fixed price delivery order. The product will be delivered to AmerisourceBergen's location in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters and...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $5,473.50, is for the supply of GEL-ONE 30 MG/3 ML SYRINGE 3ML, a medical product. The delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999.00 that AmerisourceBergen holds with the DLA Troop Support Medical, providing a comprehensive global pharmaceutical support...
- SPE2DB24D2100Indefinite Delivery Contract
- SPE2DB24D2100-SPE2DB25FBFSTDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Gel-One 30 mg/3 mL syringes with a ceiling value of $5,473.50 under a firm fixed price arrangement. The award was made on August 7, 2025, with an ultimate completion date of August 28, 2025. This non-competitive delivery order represents a small-value pharmaceutical supply transaction, with performance to be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The prime IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of medications, medical devices, and healthcare commodities to military healthcare programs and other federal customers worldwide. Gel-One is an ophthalmic viscosurgical device used in eye surgery, reflecting the company's extensive portfolio covering pharmaceutical products, vaccines, medical devices, and specialized healthcare supplies across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.5k | 8/7/25 |